Back to Search Start Over

Soy isoflavone exposure through all life stages accelerates 17β-estradiol-induced mammary tumor onset and growth, yet reduces tumor burden, in ACI rats.

Authors :
Möller FJ
Pemp D
Soukup ST
Wende K
Zhang X
Zierau O
Muders MH
Bosland MC
Kulling SE
Lehmann L
Vollmer G
Source :
Archives of toxicology [Arch Toxicol] 2016 Aug; Vol. 90 (8), pp. 1907-16. Date of Electronic Publication: 2016 Feb 09.
Publication Year :
2016

Abstract

There is an ongoing debate whether the intake of soy-derived isoflavones (sISO) mediates beneficial or adverse effects with regard to breast cancer risk. Therefore, we investigated whether nutritional exposure to a sISO-enriched diet from conception until adulthood impacts on 17β-estradiol (E2)-induced carcinogenesis in the rat mammary gland (MG). August-Copenhagen-Irish (ACI) rats were exposed to dietary sISO from conception until postnatal day 285. Silastic tubes containing E2 were used to induce MG tumorigenesis. Body weight, food intake, and tumor growth were recorded weekly. At necropsy, the number, position, size, and weight of each tumor were determined. Plasma samples underwent sISO analysis, and the morphology of MG was analyzed. Tumor incidence and multiplicity were reduced by 20 and 56 %, respectively, in the sISO-exposed rats compared to the control rats. Time-to-tumor onset was shortened from 25 to 20 weeks, and larger tumors developed in the sISO-exposed rats. The histological phenotype of the MG tumors was independent of the sISO diet received, and it included both comedo and cribriform phenotypes. Morphological analyses of the whole-mounted MGs also showed no diet-dependent differences. Lifelong exposure to sISO reduced the overall incidence of MG carcinomas in ACI rats, although the time-to-tumor was significantly shortened.

Details

Language :
English
ISSN :
1432-0738
Volume :
90
Issue :
8
Database :
MEDLINE
Journal :
Archives of toxicology
Publication Type :
Academic Journal
Accession number :
26861028
Full Text :
https://doi.org/10.1007/s00204-016-1674-2